Navigation Links
NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/5/2008

with NGX- 4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements concerning future presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX

Anthony DiTonno

(650) 358-3330

aditonno@neurogesx.com

The R
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX Closes $25 Million Private Placement
2. NeurogesX, Inc. Announces $25 Million Private Placement
3. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
4. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. NeurogesX Expands Senior Management Team
6. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
7. NeurogesX Appoints New Director to the Board
8. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
11. Genta Incorporated to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... 9 The results of a new study on immune-based ... sites around the country, will be published in the December ... MD, MS, director of the Butler Hospital Memory and Aging ... Warren Alpert Medical School of Brown University, says that this ...
... , , QUEBEC CITY, Dec. 9 /PRNewswire-FirstCall/ ... AEZ) (the "Company"), a global biopharmaceutical company focused on ... appointment of Pierre Lapalme to its Board of Directors. ... has over the course of his career held numerous ...
... , OXFORD, England, December ... Recent Recruitment of Senior Antibody Industry,Leaders and Highlights OBT,s Growth ... Oxford BioTherapeutics (OBT) has today announced the appointment of ... experience to OBT at an exciting phase in the Company,s,development, ...
Cached Biology Technology:Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2AEterna Zentaris Announces Appointment of New Board Member 2Oxford BioTherapeutics Appoints Michael Moore as Chairman 2Oxford BioTherapeutics Appoints Michael Moore as Chairman 3Oxford BioTherapeutics Appoints Michael Moore as Chairman 4
(Date:7/9/2014)... one of the amphibians with the highest distribution in ... of water where it comes into contact with the ... carried out by the Spaniard Germn Orizaola from the ... these frogs have developed a defensive response to the ... bodies if they co-exist with the crayfish. , Numerous ...
(Date:7/9/2014)... function and increase the survival rate of naturally ... School of Pharmaceutical Sciences, Southwest University, China performed ... administered with low dose of levothyroxine for 3 ... exhibited an obvious improvement in cognitive and an ... The underlying mechanism was demonstrated that levothyroxine treatment ...
(Date:7/9/2014)... vitamin D in their blood are more likely to survive ... highest levels of vitamin D have half the risk of ... reveal. , The study is the first to correlate total ... their diagnosis which includes that produced after exposure to ... long term survival prospects. , The University of Edinburgh ...
Breaking Biology News(10 mins):Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... is helping to reduce the drug cravings of addicted rats. ... some parts of the brain lose glutamate receptors from the ... neurons. The researchers have sidestepped this problem by crafting a ... glutamate receptor and, once inside a neuron, serves as a ...
... discovered in tiny snow fleas by Queen's University researchers ... transplantation. , Drs. Laurie Graham and Peter Davies, from ... produced by the fleas to protect themselves against freezing ... Celsius degrees. This would allow organs to be stored ...
... zebrafish may be able to play a critical role in ... that can lead to it - and identified one gene ... , The findings were published in a professional journal, Proceedings ... State University and two Boston hospitals, the Brigham and Women's ...
Cached Biology News:Grabbing addiction by the tail 2Grabbing addiction by the tail 3New antifreeze protein found in fleas may allow longer storage of transplant organs 2Zebrafish may hold key to improved cancer research 2Zebrafish may hold key to improved cancer research 3
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Recombinant Rat Fas Ligand/TNFSF6...
Request Info...
FGF Receptor 1 Antibody...
Biology Products: